Literature DB >> 17154263

Activation of CD4+ CD25+ regulatory T cell suppressor function by analogs of the selecting peptide.

Joseph Larkin1, Cristina Cozzo Picca, Andrew J Caton.   

Abstract

CD4+ CD25+ Foxp3+ regulatory T (Treg) cells can undergo both thymic selection and peripheral expansion in response to self peptides that are agonists for their T cell receptors (TCR). However, the specificity by which these TCR must recognize peptide:MHC complexes to activate Treg cell function is not known. We show that CD4+ CD25+ Foxp3+ Treg cells can mediate suppression in response to peptides that are only weakly cross-reactive with the self peptide that induced their formation in vivo. Moreover, suppression could be efficiently activated by peptide analogs that were inefficient at inducing CD69 up-regulation, and that also induced little or no proliferation of naïve CD4+ CD25- Foxp3- T cells expressing the same TCR. These findings provide evidence that self peptide-specific CD4+ CD25+ Foxp3+ Treg cells can exert regulatory function in response to self- and/or pathogen-derived peptides with which they are only weakly cross-reactive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154263     DOI: 10.1002/eji.200636577

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

Review 1.  How specificity for self-peptides shapes the development and function of regulatory T cells.

Authors:  Donald M Simons; Cristina Cozzo Picca; Soyoung Oh; Olivia A Perng; Malinda Aitken; Jan Erikson; Andrew J Caton
Journal:  J Leukoc Biol       Date:  2010-05-21       Impact factor: 4.962

Review 2.  What roles do regulatory T cells play in the control of the adaptive immune response?

Authors:  Melvin Cohn
Journal:  Int Immunol       Date:  2008-07-25       Impact factor: 4.823

3.  Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells.

Authors:  Rafal Pacholczyk; Joanna Kern; Nagendra Singh; Makio Iwashima; Piotr Kraj; Leszek Ignatowicz
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

Review 4.  Autologous regulatory T cells for the treatment of type 1 diabetes.

Authors:  James A Thompson; Daniel Perry; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

5.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

6.  Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus.

Authors:  Tony Schountz; Joseph Prescott; Ann C Cogswell; Lauren Oko; Katy Mirowsky-Garcia; Alejandra P Galvez; Brian Hjelle
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

7.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

8.  Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance.

Authors:  J I Kim; M K Lee; D J Moore; S B Sonawane; P E Duff; M R O'Connor; H Yeh; M M Lian; S Deng; A J Caton; J F Markmann
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

9.  Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.

Authors:  Sanjay Sharma; Ana Lucia Dominguez; Soraya Zorro Manrique; Federica Cavallo; Shimon Sakaguchi; Joseph Lustgarten
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

10.  Epigenetic modification of FOXP3 in patients with chronic HIV infection.

Authors:  Enass A Abdel-Hameed; Hong Ji; Kenneth E Sherman; Mohamed T M Shata
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.